与瘤相关的碳水化合物抗原:生物标志物的发现和临床应用
在PubMed上查看摘要
概括
此摘要是机器生成的。瘤相关碳水化合物抗原 (TACA) 是独特的癌细胞标记物. 测量TACA有助于早期诊断,预后和向癌症免疫疗法.
科学领域
- 癌症学
- 葡萄糖生物学
- 癌症生物标志物
背景情况
- 瘤相关碳水化合物抗原 (TACA) 是癌细胞过度表达的异常糖化产物.
- 这些抗原对瘤进展至关重要,影响转移和免疫逃避.
- 在各种恶性瘤中,TACA升高与患者预后不佳相关.
研究的目的
- 突出TACA作为癌症生物标志物的重要性.
- 探索TACA的诊断和治疗潜力.
- 在液体活检和癌症免疫治疗的背景下讨论TACA.
主要方法
- 关于TACA表达和癌症功能的文献综述.
- 对TACA在瘤进展和临床结果中的作用的分析.
- 基于TACA的诊断测定和治疗策略的评估.
主要成果
- 在瘤细胞上选择性表达TACA,使其成为理想的生物标志物.
- 在血清中定量TACAs可用于早期癌症检测和监测.
- 在癌症疫苗,抗体疗法和CAR T细胞治疗中,TACA是有前途的目标.
结论
- 在癌症检测,预后和监测方面,TACA是有价值的生物标志物.
- 基于TACA的液体活检为癌症治疗提供了一种非侵入性方法.
- 在免疫治疗中向TACA具有显著的改善癌症治疗结果的潜力.
相关概念视频
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

